<DOC>
	<DOCNO>NCT02386098</DOCNO>
	<brief_summary>The purpose study evaluate whether combination BMS-955176 atazanavir ( ATV ) [ without ritonavir ( RTV ) ] dolutegravir ( DTG ) efficacious , safe , well-tolerated HIV-1 infect treatment experienced adult .</brief_summary>
	<brief_title>Strategy-confirming Study BMS-955176 Treat HIV-1 Infected Treatment-experienced Adults</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Men nonpregnant woman , least 18 year age Antiretroviral treatmentexperienced , define documented evidence fail 1 2 regimen include 2 3 class antiretroviral ( ARV ) ( without document resistance ) CD4+ Tcell count &gt; 50 cells/mm3 Screening genotype/phenotype indicate susceptibility study drug ( unboosted ATV , FC &lt; 2.2 ; DTG ; TDF ) Antiretroviral treatmentexperienced adult fail &gt; 2 ARV regimen Resistance partial resistance study drug determine test Screening Historical document genotypic and/or phenotypic drug resistance test show certain resistance mutation ATV , TDF , RAL , Protease Inhibitors , certain TAMs Chronic hepatitis B virus ( HBV ) / hepatitis C virus ( HCV ) Blood test indicate normal liver function Hemoglobin &lt; 8.0 g/dL , Platelets &lt; 50,000 cells/mm3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>